Lysin polypeptides active against Gram-negative bacteria
AssigneeContrafect Corporation
InventorsRaymond Schuch, Simon Hoffenberg, Michael Wittekind
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.
Claims14
A pharmaceutical composition comprising an isolated lysin polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 9, and SEQ ID NO:
- 10;
- and a pharmaceutically acceptable carrier.
An isolated polypeptide, comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 9, and SEQ ID NO:
- 10.
A method of inhibiting the growth, or reducing the population, or killing of at least one species of Gram-negative bacteria, the method comprising contacting the bacteria with a composition comprising an effective amount of a lysin polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 6, SEQ ID NO:
- 9, and SEQ ID NO:
- 10, wherein the lysin polypeptide has the property of inhibiting the growth of, or reducing an initial population of, or killing P. aeruginosa and optionally at least one other species of Gram-negative bacteria.
Dependencies are inferred from the claim text.